Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 18/20 | 0.46 |
| ▸ | PDE1C | Q14123 | 9/20 | 0.42 |
| ▸ | PDE1A | P54750 | 8/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27193455 | 0.90 | PDE1B (0.47) | PDE1BPDE1CPDE1ACNR1CNR2 | |
| SCHEMBL16535998 | 0.84 | PDE1B (0.44) | PDE1BCNR1CNR2 | |
| SCHEMBL1592906 | 0.83 | PDE1B (0.55) | PDE1BPDE1CPDE1ACNR1CNR2 | |
| SCHEMBL16540160 | 0.81 | PDE4A (0.42) | PDE1B | |
| SCHEMBL1592961 | 0.80 | PDE1B (0.53) | PDE1BPDE1CPDE1ACNR1CNR2 | |
| SCHEMBL31533714 | 0.80 | PDE1B (0.45) | PDE1BPDE1CPDE1ACNR1CNR2 | |
| SCHEMBL27193403 | 0.80 | PDE1B (0.45) | PDE1BPDE1CPDE1ACNR1CNR2 | |
| SCHEMBL27193665 | 0.80 | PDE1B (0.45) | PDE1BPDE1CPDE1ACNR1CNR2 | |
| SCHEMBL16536339 | 0.79 | PDE1B (0.51) | PDE1BCNR1CNR2SMN1; SMN2 | |
| SCHEMBL23069164 | 0.78 | PDE1B (0.50) | PDE1BCNR1CNR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119654314-A | Heterocyclic amide and urea compounds as JAK2 inhibitors | 艾捷斯治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240116892-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116892-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | JAK2, JAK1, JAK3 | PDE1B 2544/4885PDE1C 2803/4885PDE1A 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.